Optical coherence tomography-guided versus angiography-guided percutaneous coronary intervention for patients with complex lesions (OCCUPI): an investigator-initiated, multicentre, randomised, open-label, superiority trial in South Korea.

IF 98.4 1区 医学 Q1 MEDICINE, GENERAL & INTERNAL
The Lancet Pub Date : 2024-09-14 Epub Date: 2024-09-02 DOI:10.1016/S0140-6736(24)01454-5
Sung-Jin Hong, Seung-Jun Lee, Sang-Hyup Lee, Jong-Young Lee, Deok-Kyu Cho, Jin Won Kim, Sang Min Kim, Seung-Ho Hur, Jung Ho Heo, Ji-Yong Jang, Jin Sin Koh, Hoyoun Won, Jun-Won Lee, Soon Jun Hong, Dong-Kie Kim, Jeong Cheon Choe, Jin Bae Lee, Soo-Joong Kim, Tae-Hyun Yang, Jung-Hee Lee, Young Joon Hong, Jong-Hwa Ahn, Yong-Joon Lee, Chul-Min Ahn, Jung-Sun Kim, Young-Guk Ko, Donghoon Choi, Myeong-Ki Hong, Yangsoo Jang, Byeong-Keuk Kim
{"title":"Optical coherence tomography-guided versus angiography-guided percutaneous coronary intervention for patients with complex lesions (OCCUPI): an investigator-initiated, multicentre, randomised, open-label, superiority trial in South Korea.","authors":"Sung-Jin Hong, Seung-Jun Lee, Sang-Hyup Lee, Jong-Young Lee, Deok-Kyu Cho, Jin Won Kim, Sang Min Kim, Seung-Ho Hur, Jung Ho Heo, Ji-Yong Jang, Jin Sin Koh, Hoyoun Won, Jun-Won Lee, Soon Jun Hong, Dong-Kie Kim, Jeong Cheon Choe, Jin Bae Lee, Soo-Joong Kim, Tae-Hyun Yang, Jung-Hee Lee, Young Joon Hong, Jong-Hwa Ahn, Yong-Joon Lee, Chul-Min Ahn, Jung-Sun Kim, Young-Guk Ko, Donghoon Choi, Myeong-Ki Hong, Yangsoo Jang, Byeong-Keuk Kim","doi":"10.1016/S0140-6736(24)01454-5","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Despite the detailed imaging information provided by optical coherence tomography (OCT) during percutaneous coronary intervention (PCI), clinical benefits of this imaging technique in this setting remain uncertain. The aim of the OCCUPI trial was to compare the clinical benefits of OCT-guided versus angiography-guided PCI for complex lesions, assessed as the rate of major adverse cardiac events at 1 year.</p><p><strong>Methods: </strong>This investigator-initiated, multicentre, randomised, open-label, superiority trial conducted at 20 hospitals in South Korea enrolled patients aged 19-85 years for whom PCI with drug-eluting stents was clinically indicated. After diagnostic angiography, clinical and angiographic findings were assessed to identify patients who met the criterion of having one or more complex lesions. Patients were randomly assigned 1:1 to receive PCI with OCT guidance (OCT-guidance group) or angiography guidance without OCT (angiography-guidance group). Web-response permuted-block randomisation (mixed blocks of four or six) was used at each participating site to allocate patients. The allocation sequence was computer-generated by an external programmer who was not involved in the rest of the trial. Outcome assessors were masked to group assignment. Patients, follow-up health-care providers, and data analysers were not masked. PCI was done according to conventional standard methods with everolimus-eluting stents. The primary endpoint was major adverse cardiac events (a composite of cardiac death, myocardial infarction, stent thrombosis, or ischaemia-driven target-vessel revascularisation), 1 year after PCI. The primary analysis was done in the intention-to-treat population. The margin used to establish superiority was 1·0 as a hazard ratio. This trial is registered with ClinicalTrials.gov (NCT03625908) and is completed.</p><p><strong>Findings: </strong>Between Jan 9, 2019, and Sept 22, 2022, 1604 patients requiring PCI with drug-eluting stents for complex lesions were randomly assigned to receive either OCT-guided PCI (n=803) or angiography-guided PCI (n=801). 1290 (80%) of 1604 patients were male and 314 (20%) were female. The median age of patients at randomisation was 64 years (IQR 57-70). 1588 (99%) patients completed 1-year follow-up. The primary endpoint occurred in 37 (5%) of 803 patients in the OCT-guided PCI group and 59 (7%) of 801 patients in the angiography-guided PCI group (absolute difference -2·8% [95% CI -5·1 to -0·4]; hazard ratio 0·62 [95% CI 0·41 to 0·93]; p=0·023). Rates of stroke, bleeding events, and contrast-induced nephropathy were not significantly different across the two groups.</p><p><strong>Interpretation: </strong>Among patients who required drug-eluting stent implantation for complex lesions, OCT guidance resulted in a lower incidence of major adverse cardiac events at 1 year compared with angiography guidance. These findings indicate the existence of a therapeutic benefit of OCT as an intravascular imaging technique for PCI guidance in patients with complex coronary lesions.</p><p><strong>Funding: </strong>Abbott Vascular and Cardiovascular Research Center.</p><p><strong>Translation: </strong>For the Korean translation of the abstract see Supplementary Materials section.</p>","PeriodicalId":18014,"journal":{"name":"The Lancet","volume":null,"pages":null},"PeriodicalIF":98.4000,"publicationDate":"2024-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Lancet","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/S0140-6736(24)01454-5","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/9/2 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Despite the detailed imaging information provided by optical coherence tomography (OCT) during percutaneous coronary intervention (PCI), clinical benefits of this imaging technique in this setting remain uncertain. The aim of the OCCUPI trial was to compare the clinical benefits of OCT-guided versus angiography-guided PCI for complex lesions, assessed as the rate of major adverse cardiac events at 1 year.

Methods: This investigator-initiated, multicentre, randomised, open-label, superiority trial conducted at 20 hospitals in South Korea enrolled patients aged 19-85 years for whom PCI with drug-eluting stents was clinically indicated. After diagnostic angiography, clinical and angiographic findings were assessed to identify patients who met the criterion of having one or more complex lesions. Patients were randomly assigned 1:1 to receive PCI with OCT guidance (OCT-guidance group) or angiography guidance without OCT (angiography-guidance group). Web-response permuted-block randomisation (mixed blocks of four or six) was used at each participating site to allocate patients. The allocation sequence was computer-generated by an external programmer who was not involved in the rest of the trial. Outcome assessors were masked to group assignment. Patients, follow-up health-care providers, and data analysers were not masked. PCI was done according to conventional standard methods with everolimus-eluting stents. The primary endpoint was major adverse cardiac events (a composite of cardiac death, myocardial infarction, stent thrombosis, or ischaemia-driven target-vessel revascularisation), 1 year after PCI. The primary analysis was done in the intention-to-treat population. The margin used to establish superiority was 1·0 as a hazard ratio. This trial is registered with ClinicalTrials.gov (NCT03625908) and is completed.

Findings: Between Jan 9, 2019, and Sept 22, 2022, 1604 patients requiring PCI with drug-eluting stents for complex lesions were randomly assigned to receive either OCT-guided PCI (n=803) or angiography-guided PCI (n=801). 1290 (80%) of 1604 patients were male and 314 (20%) were female. The median age of patients at randomisation was 64 years (IQR 57-70). 1588 (99%) patients completed 1-year follow-up. The primary endpoint occurred in 37 (5%) of 803 patients in the OCT-guided PCI group and 59 (7%) of 801 patients in the angiography-guided PCI group (absolute difference -2·8% [95% CI -5·1 to -0·4]; hazard ratio 0·62 [95% CI 0·41 to 0·93]; p=0·023). Rates of stroke, bleeding events, and contrast-induced nephropathy were not significantly different across the two groups.

Interpretation: Among patients who required drug-eluting stent implantation for complex lesions, OCT guidance resulted in a lower incidence of major adverse cardiac events at 1 year compared with angiography guidance. These findings indicate the existence of a therapeutic benefit of OCT as an intravascular imaging technique for PCI guidance in patients with complex coronary lesions.

Funding: Abbott Vascular and Cardiovascular Research Center.

Translation: For the Korean translation of the abstract see Supplementary Materials section.

针对复杂病变患者的光学相干断层扫描引导经皮冠状动脉介入治疗(OCCUPI)与血管造影引导经皮冠状动脉介入治疗(OCCUPI):在韩国进行的一项由研究者发起的多中心、随机、开放标签、优越性试验。
背景:尽管光学相干断层扫描(OCT)可在经皮冠状动脉介入治疗(PCI)过程中提供详细的成像信息,但这种成像技术在这种情况下的临床获益仍不确定。OCCUPI 试验的目的是比较 OCT 引导下与血管造影引导下 PCI 治疗复杂病变的临床优势,评估指标为 1 年后主要不良心脏事件的发生率:这项由研究者发起的多中心、随机、开放标签、优越性试验在韩国 20 家医院进行,招募了年龄在 19-85 岁之间、有临床指征使用药物洗脱支架进行 PCI 治疗的患者。在诊断性血管造影后,对临床和血管造影结果进行评估,以确定符合一个或多个复杂病变标准的患者。患者以1:1的比例随机分配接受有OCT引导的PCI(OCT引导组)或无OCT引导的血管造影(血管造影引导组)。每个参与研究的机构都采用了网络响应包块随机分配法(4或6个混合包块)来分配患者。分配序列由外部程序员通过计算机生成,该程序员不参与试验的其他部分。结果评估人员对组别分配进行了屏蔽。患者、随访医护人员和数据分析人员均未蒙面。PCI按照常规标准方法进行,使用依维莫司洗脱支架。主要终点是PCI术后1年的主要心脏不良事件(心脏死亡、心肌梗死、支架血栓或缺血导致的靶血管血运重建的综合)。主要分析是在意向治疗人群中进行的。确定优越性的边际值为1-0,即危险比。该试验已在ClinicalTrials.gov(NCT03625908)注册,并已完成:2019年1月9日至2022年9月22日期间,1604名需要使用药物洗脱支架PCI治疗复杂病变的患者被随机分配接受OCT引导的PCI(803人)或血管造影引导的PCI(801人)。1604名患者中有1290人(80%)为男性,314人(20%)为女性。随机化时患者的中位年龄为 64 岁(IQR 57-70)。1588名(99%)患者完成了为期1年的随访。OCT引导PCI组803例患者中有37例(5%)出现主要终点,血管造影引导PCI组801例患者中有59例(7%)出现主要终点(绝对差异-2-8% [95% CI -5-1 to -0-4];危险比0-62 [95% CI 0-41 to 0-93];P=0-023)。中风、出血事件和造影剂诱发肾病的发生率在两组间无显著差异:在需要植入药物洗脱支架治疗复杂病变的患者中,OCT引导与血管造影引导相比,1年后主要不良心脏事件的发生率更低。这些研究结果表明,OCT作为一种血管内成像技术,对复杂冠状动脉病变患者的PCI引导具有治疗效果:雅培血管与心血管研究中心:摘要韩文译文见补充材料部分。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
The Lancet
The Lancet 医学-医学:内科
CiteScore
148.10
自引率
0.70%
发文量
2220
审稿时长
3 months
期刊介绍: The Lancet is a world-leading source of clinical, public health, and global health knowledge. It was founded in 1823 by Thomas Wakley and has been an independent, international weekly general medical journal since then. The journal has an Impact Factor of 168.9, ranking first among 167 general and internal medicine journals globally. It also has a Scopus CiteScore of 133·2, ranking it second among 830 general medicine journals. The Lancet's mission is to make science widely available to serve and transform society, positively impacting people's lives. Throughout its history, The Lancet has been dedicated to addressing urgent topics, initiating debate, providing context for scientific research, and influencing decision makers worldwide.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信